Showing 2663 results
- Media Release /If approved, Zykadia (ceritinib) would be the first treatment option for patients in Europe with ALK+ NSCLC previously treated with crizotinib ALK+ NSCLC is driven by a rearrangement of the…
- Media Release /Les actionnaires approuvent la 18e hausse consécutive du dividende, à CHF 2,60 par action (+6 %) au titre de l'exercice 2014. De même que d'autres administrateurs qui étaient candidats à leur…
- Media Release /Phase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration Data shows the potential for less…
- Media Release /Shareholders approve 18th consecutive dividend increase to CHF 2.60 (+6%) per share for 2014 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well…
- Media Release /Mit GSK abgeschlossene Transaktionen: Übernahme des Onkologie-Portfolios von GSK, Schaffung eines Joint Venture für Consumer Healthcare und Veräusserung des Bereichs Vaccines (ohne Grippeimpfstoffe…
- Media Release /Conclusion des transactions avec GSK incluant : l'acquisition du portefeuille oncologie de GSK, la création d'une coentreprise de Consumer Healthcare et la cession de l'activité vaccins (hors…
- Media Release /Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus…
- Media Release /Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the…
- Media Release /Detailed results from the CLEAR study will be revealed showing Cosentyx superiority to Stelara® in clearing skin (PASI 90 and PASI 100)[1] New data from the long-term Phase III program to…
- Media Release /Jakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with…